Jump to ContentJump to Main Navigation
Oxford Textbook of Medicine$
Users without a subscription are not able to see the full content.

Edited by David A. Warrell, Timothy M. Cox, John D. Firth

Online access to the Oxford Textbook of Medicine in low and middle income countries is available through the World Health Organization-led HINARI Access to Research in Health programme

Latest update

The November 2012 update sees updates to over 70 chapters, focusing on Neurology and Gastroenterology. This update also incorporates a selection of 29 Case Histories taken from related titles in the Oxford Case Histories series, linked to from related chapters. Each case includes several questions followed by detailed answers and discussion to enhance diagnostic and clinical understanding.

Neurology updates include substantial updates to key chapters and new material on a wide range of topics including spinal cord injury, autonomic nervous system disorders, and inherited neurodegenerative diseases. 

Gastroenterology updates
include extensive revisions of key chapters on liver failure and acute pancreatitis and new material on a wide range of matters, ranging from the common to the rare: including surgical treatments for colonic diverticular disease, antibody tests for immune disorders, and a revised treatment algorithm for small bowel bacterial overgrowth.

Access token activation

If you have an access token, please click here to activate it.

Sign up for an individual subscription to the Oxford Textbook of Medicine.

Subscriber Login

Forgotten your password?

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Contents

Psychopharmacology in medical practice

Chapter:
Psychopharmacology in medical practice
Author(s):

Philip J. Cowen

DOI:
10.1093/med/9780199204854.003.260601

Psychotropic drugs play an indispensable role in the treatment of severe psychiatric illness such as schizophrenia and bipolar disorder. They are often used to treat other conditions, particularly depression and anxiety disorders, but for these disorders nondrug treatments are effective and—if available—are often preferred by patients.

Antidepressants—newer drugs, particularly selective serotonin reuptake inhibitors (SSRIs), have replaced traditional tricyclic antidepressants in the treatment of depression. These are somewhat better tolerated and, with the exception of venlafaxine, are safer in overdose. All patients should be monitored carefully following the introduction of antidepressant medication because the risk of suicidal behaviour appears to be higher at this time. Patients with recurrent depression often benefit from maintenance treatment with antidepressants.

Lithium—this continues to be the leading mood stabilizing agent prescribed for the treatment of bipolar disorder in the United Kingdom, but it has significant adverse effects that particularly involve the kidneys and central nervous system. It also has a narrow therapeutic index and drug interactions carry a high risk of serious toxicity. For these reasons there is growing use of anticonvulsant drugs such as sodium valproate as alternatives to lithium.

Antipsychotics—in the treatment of schizophrenia, atypical antipsychotic drugs are replacing conventional agents such as haloperidol and chlorpromazine because of their better perceived adverse effect profile, particularly with regard to extrapyramidal movement disorders. However, some atypical agents, particularly clozapine and olanzapine, cause excessive weight gain and have been linked with type 2 diabetes and disturbances in lipid metabolism. Of these agents, only clozapine has clearly superior efficacy relative to conventional agents, but it carries a risk of agranulocytosis and hence the need for weekly blood count monitoring complicates its use.

Benzodiazepines—use of these drugs for the treatment of anxiety and insomnia continues to decline because of their recognized liability to cause tolerance and dependence. They are indicated only for short-term use, preferably on an as needed basis. The same advice applies to other hypnotic agents such as the ‘Z’ drugs. Where psychological treatments are not effective or unavailable, antidepressants treatment—particularly with SSRIs—can be used to treat a range of anxiety disorders, including obsessive–compulsive disorder.

Oxford Medicine requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us.